Alliancebernstein L.P. grew its holdings in Intersect ENT Inc (NASDAQ:XENT) by 12.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,466,730 shares of the medical equipment provider’s stock after purchasing an additional 161,723 shares during the period. Alliancebernstein L.P. owned about 4.98% of Intersect ENT worth $47,522,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also added to or reduced their stakes in the business. Geode Capital Management LLC increased its stake in Intersect ENT by 4.8% in the fourth quarter. Geode Capital Management LLC now owns 256,482 shares of the medical equipment provider’s stock worth $8,309,000 after purchasing an additional 11,701 shares during the period. BlackRock Inc. increased its stake in Intersect ENT by 2.0% in the fourth quarter. BlackRock Inc. now owns 1,980,942 shares of the medical equipment provider’s stock worth $64,183,000 after purchasing an additional 39,761 shares during the period. Capital Fund Management S.A. purchased a new stake in Intersect ENT in the fourth quarter worth $483,000. Advisory Research Inc. increased its stake in Intersect ENT by 58.9% in the fourth quarter. Advisory Research Inc. now owns 74,112 shares of the medical equipment provider’s stock worth $2,401,000 after purchasing an additional 27,480 shares during the period. Finally, Wells Fargo & Company MN increased its stake in Intersect ENT by 64.1% in the fourth quarter. Wells Fargo & Company MN now owns 84,483 shares of the medical equipment provider’s stock worth $2,738,000 after purchasing an additional 33,007 shares during the period. Institutional investors and hedge funds own 84.49% of the company’s stock.
In related news, CFO Jeryl L. Hilleman sold 12,835 shares of the firm’s stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $33.81, for a total transaction of $433,951.35. Following the sale, the chief financial officer now owns 25,767 shares of the company’s stock, valued at $871,182.27. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Lisa D. Earnhardt sold 10,685 shares of the firm’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $31.87, for a total value of $340,530.95. Following the sale, the insider now directly owns 487,868 shares in the company, valued at approximately $15,548,353.16. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 136,310 shares of company stock worth $4,660,238. Insiders own 13.70% of the company’s stock.
Intersect ENT Inc (XENT) opened at $38.75 on Wednesday. The company has a market capitalization of $1,190.00, a price-to-earnings ratio of -69.20 and a beta of 0.80. Intersect ENT Inc has a 52 week low of $14.60 and a 52 week high of $39.30.
Intersect ENT (NASDAQ:XENT) last announced its quarterly earnings results on Tuesday, February 27th. The medical equipment provider reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.06. The firm had revenue of $29.53 million for the quarter, compared to analyst estimates of $29.45 million. Intersect ENT had a negative return on equity of 14.40% and a negative net margin of 16.99%. analysts forecast that Intersect ENT Inc will post -0.59 earnings per share for the current fiscal year.
About Intersect ENT
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Want to see what other hedge funds are holding XENT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intersect ENT Inc (NASDAQ:XENT).
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.